Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$13.80M$13.80Mderived+47.1% vs Q4 2024 Net Income-$47.24M-$47.24MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$46,039,000N/M Operating Cash Flowderived-$48,314,000N/M Free Cash Flowderived-$48,314,000N/M Margins · derivedOperating margin-333.6%+51.6 pt vs Q4 2024
Net margin-342.3%+9.8 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 17, 2026 · 76 d after period end